The stock has now broken below S-1 support at $2.92, confirmed by a large red candle signaling a clear downside breakout. With small-cap biotech under heavy pressure, a move toward S-2 support at $1.84 (dating back to Oct. 2023) is now a real possibility.
Not trying to pick on the stock — just calling what’s in front of us. I’ve held off buying so far, and looking back, that patience is paying off. Still watching for a better entry. Stay tuned.
Not trying to pick on the stock — just calling what’s in front of us. I’ve held off buying so far, and looking back, that patience is paying off. Still watching for a better entry. Stay tuned.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。